IRIS
PALA, Daniele
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.048
AS - Asia 1.905
EU - Europa 1.412
SA - Sud America 226
AF - Africa 116
OC - Oceania 1
Totale 5.708
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.994
SG - Singapore 640
CN - Cina 574
FI - Finlandia 319
VN - Vietnam 311
IE - Irlanda 245
IT - Italia 230
SE - Svezia 209
BR - Brasile 177
DE - Germania 136
HK - Hong Kong 129
TR - Turchia 82
FR - Francia 76
ZA - Sudafrica 74
NL - Olanda 48
GB - Regno Unito 39
IN - India 35
CA - Canada 26
AR - Argentina 24
BE - Belgio 23
CI - Costa d'Avorio 22
UA - Ucraina 21
MX - Messico 19
JP - Giappone 17
BD - Bangladesh 14
IQ - Iraq 14
RU - Federazione Russa 13
PH - Filippine 12
ES - Italia 10
ID - Indonesia 10
JO - Giordania 9
MA - Marocco 8
PK - Pakistan 8
TH - Thailandia 8
CZ - Repubblica Ceca 7
LT - Lituania 7
VE - Venezuela 7
EC - Ecuador 5
HU - Ungheria 5
PL - Polonia 5
CL - Cile 4
PS - Palestinian Territory 4
SA - Arabia Saudita 4
AE - Emirati Arabi Uniti 3
AL - Albania 3
AT - Austria 3
AZ - Azerbaigian 3
BO - Bolivia 3
CO - Colombia 3
HN - Honduras 3
IL - Israele 3
KE - Kenya 3
KR - Corea 3
NP - Nepal 3
PY - Paraguay 3
TN - Tunisia 3
TW - Taiwan 3
AO - Angola 2
KG - Kirghizistan 2
LV - Lettonia 2
MD - Moldavia 2
MY - Malesia 2
OM - Oman 2
QA - Qatar 2
RO - Romania 2
SN - Senegal 2
UZ - Uzbekistan 2
AM - Armenia 1
BG - Bulgaria 1
BH - Bahrain 1
CH - Svizzera 1
CY - Cipro 1
DO - Repubblica Dominicana 1
EE - Estonia 1
EG - Egitto 1
ET - Etiopia 1
GR - Grecia 1
GT - Guatemala 1
HR - Croazia 1
KZ - Kazakistan 1
LK - Sri Lanka 1
NI - Nicaragua 1
NO - Norvegia 1
PA - Panama 1
SK - Slovacchia (Repubblica Slovacca) 1
SV - El Salvador 1
SY - Repubblica araba siriana 1
TV - Tuvalu 1
VG - Isole Vergini Britanniche 1
Totale 5.708
Salva come PNG Salva come JPEG
Città #
Singapore 341
Ashburn 245
Dublin 245
Chandler 238
San Jose 183
Santa Clara 148
Dallas 142
Beijing 140
Parma 131
Hong Kong 118
Ho Chi Minh City 97
Dearborn 82
Hanoi 75
Izmir 71
Johannesburg 71
Boardman 69
Ann Arbor 66
Nanjing 63
Shanghai 50
Los Angeles 46
New York 44
Bremen 42
Princeton 42
Jacksonville 38
Lauterbourg 38
Munich 37
Wilmington 35
Helsinki 25
Abidjan 22
Brussels 21
Columbus 21
San Mateo 20
Kunming 19
Shenyang 19
São Paulo 16
Düsseldorf 15
Hebei 15
Hefei 15
Tokyo 15
Nanchang 14
Seattle 13
Turku 13
Jinan 12
Toronto 12
Guangzhou 11
Haiphong 11
Jiaxing 11
Moscow 11
Buffalo 10
Changsha 10
Da Nang 10
London 10
Chennai 9
Hangzhou 9
Amman 8
Atlanta 8
Montreal 8
Orem 8
Phoenix 8
Rio de Janeiro 8
Tianjin 8
Belo Horizonte 7
Boston 7
Brooklyn 7
Jakarta 7
Milan 7
Norwalk 7
Pune 7
Stockholm 7
The Dalles 7
Woodbridge 7
Can Tho 6
Council Bluffs 6
Mexico City 6
Modena 6
Ninh Bình 6
Poplar 6
Rome 6
Bangkok 5
Denver 5
Fremont 5
Grafing 5
Porto Alegre 5
San Francisco 5
Zhengzhou 5
Ankara 4
Baghdad 4
Borås 4
Brescia 4
Fuzhou 4
Haikou 4
Hyderabad 4
Lahore 4
New Delhi 4
Nova Iguaçu 4
Nuremberg 4
Olomouc 4
Shijiazhuang 4
Springfield 4
Taizhou 4
Totale 3.549
Salva come PNG Salva come JPEG
Nome #
Inhibition of Eph/ephrin interaction with the small molecule UniPR500 improves glucose tolerance in healthy and insulin-resistant mice 240
Dibasic biphenyl H(3) receptor antagonists: Steric tolerance for a lipophilic side chain. 204
Development of an orally bioavailable small molecule targeting Eph-ephrin system: in vitro and in vivo anticancer activity. 202
Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. 200
UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations. 197
Combining ligand- and structure-based approaches for the discovery of new inhibitors of the EPHA2-ephrin-A1 interaction 196
Discovery and development of Eph-ephrin antagonists endowed with antiangiogenic properties 192
Design and structure-activity relationship of amino acid derivatives of lithocholic acid as novel EphA2 antagonists 182
Atropisomerism and Conformational Equilibria: Impact on PI3Kδ Inhibition of 2-((6-Amino-9H-purin-9-yl)methyl)-5-methyl-3-(o-tolyl)quinazolin-4(3H)-one (IC87114) and Its Conformationally Restricted Analogs 174
270 Discovery, development and optimization of low molecular weight EPH–ephrin protein–protein inhibitors 166
Development of 3-oxo-cholenic derivatives as Eph antagonists able to block in vitro angiogenesis 162
Multiple approaches for the discovery and development of small molecules targeting Eph-ephrin protein-protein interaction 160
Biochemical characterization of EphA2 antagonists with improved physico-chemical properties by cell-based assays and surface plasmon resonance analysis 155
Design and structure-activity relationships of amino acid derivatives of lithocholic acid as novel EphA2 receptor antagonists. 148
Δ5-Cholenoyl-amino acids as selective and orally available antagonists of the Eph-ephrin system 148
Exploiting Free-Energy Minima to Design Novel EphA2 Protein-Protein Antagonists: From Simulation to Experiment and Return 147
Comparative Analysis of Virtual Screening Approaches in the Search for Novel EphA2 Receptor Antagonists 145
Discovery and development of low molecular weight Eph-ephrin protein-protein inhbi-tors endowed with antiangiogenic activity 144
Combining pharmacology, target hopping and computational medicinal chemistry to discover novel scaffold targeting EPH-ephrin interaction. 143
Toward the Definition of Stereochemical Requirements for MT(2)-Selective Antagonists and Partial Agonists by Studying 4-Phenyl-2-propionamidotetralin Derivatives. 141
Metadynamics for perspective drug design: Computationally driven synthesis of new protein-protein interaction inhibitors targeting the EphA2 receptor 138
Computer-Aided Design of Novel Antagonists of the EphA2 Receptor 135
Target Hopping as a Useful Tool for the Identification of Novel EphA2 Protein–Protein Antagonists 133
Metadynamics Simulations Distinguish Short- and Long-Residence-Time Inhibitors of Cyclin-Dependent Kinase 8. 133
Free-energy studies reveal a possible mechanism for oxidation-dependent inhibition of MGL 131
Complex product composition generates risks for generic substitution also with dosage forms for intravenous administration 127
New classes of potent heparanase inhibitors from ligand-based virtual screening 124
Target-hopping: a useful approach to identify novel Eph receptor antagonists 122
Highly Potent and Selective MT2 Melatonin Receptor Full Agonists from Conformational Analysis of 1-Benzyl-2-acylaminomethyl-tetrahydroquinolines 119
Synthesis and Structure-Activity Relationships of Amino Acid Conjugates of Cholanic Acid as Antagonists of the EphA2 Receptor. 118
Homology models of melatonin receptors: challenges and recent advances. 117
ST7612AA1, a thioacetate-ω(γ-lactam carboxamide) derivative selected from a novel generation of oral HDAC inhibitors 108
Synthesis and characterization of new bivalent agents as melatonin- and histamine h3-ligands. 101
Synthesis of (E)-8-(3-chlorostyryl)caffeine analogs leading to 9-deazaxanthine derivatives as dual A2A antagonists /MAO-B inhibitors. 95
Recent advances in the development of melatonin MT(1) and MT(2) receptor agonists. 94
In vitro and in vivo efficacy of an orally bioavailable antagonist of Eph-ephrin system in tumor angiogenesis and growth 89
Towards the development of 5-HT7 ligands combining serotonin-like and arylpiperazine moieties 85
Structure-based virtual screening of MT2 melatonin receptor: influence of template choice and structural refinement. 80
Synthesis, structure and inhibitory activity of a stereoisomer of oseltamivir carboxylate 79
Kinetic analysis and molecular modeling of the inhibition mechanism of roneparstat (SST0001) on human heparanase 78
Therapeutic uses of melatonin and melatonin derivatives: a patent review (2012 - 2014) 75
MT1-Selective Melatonin Receptor Ligands: Synthesis, Pharmacological Evaluation, and Molecular Dynamics Investigation of N-[[(3-O-Substituted)anilino]alkyl]amides. 75
Totale 5.802
Salva come PNG Salva come JPEG
Categoria #
all - tutte 18.832
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.832
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202133 0 0 0 0 0 0 0 0 0 13 12 8
2021/2022184 6 2 3 28 2 7 8 25 7 14 16 66
2022/2023891 99 107 39 60 103 97 14 48 299 2 21 2
2023/2024288 16 27 4 13 21 61 36 24 8 14 24 40
2024/2025994 26 64 61 55 120 109 49 45 132 76 97 160
2025/20262.139 212 269 235 188 291 132 260 74 332 146 0 0
Totale 5.802